Myopia Prevention: Red Light Leads, Sleep Falls Short

Outdoor time remains the practical first move for children at risk of myopia. But a 2025 network meta-analysis suggests it may not produce the largest measured refractive effect. In 19 randomized trials involving 14,173 pre-myopic children, low-level red-light therapy ranked first, low-dose atropine ranked second, and outdoor activities ranked third for annual refractive change. The finding is intriguing. It is not a license to buy a red-light device online and point it at a six-year-old.

The reason is simple: every prevention trial in the analysis came from Asian populations, long-term outcomes remain unknown, and safety evidence in non-myopic eyes is thin. Meanwhile, the sleep advice often bundled into myopia-prevention messaging has a much weaker foundation. A systematic review found contradictory questionnaire-based results, while the one study using wrist-worn objective sleep measurement found no association with refractive change or axial elongation.

The first prevention ranking puts red light first

Lee et al.'s 2025 network meta-analysis examined five interventions in children who had not yet become myopic but were considered at risk. The 19 randomized controlled trials included 14,173 children, with a mean age of 6.77 years and mean baseline spherical equivalent refraction of +0.88 D.

For annual refractive change, low-level red-light therapy (LLRL) ranked first by P-score, with a mean difference of +0.48 D/year versus control (95% CI, +0.38 to +0.59). Low-dose atropine followed at +0.33 D/year (95% CI, +0.23 to +0.43). Outdoor activity had a smaller but statistically significant benefit of +0.11 D/year (95% CI, +0.03 to +0.19).

Exercise produced an estimated +0.12 D/year benefit, but its 95% CI ranged from −0.02 to +0.27, so the result was not statistically significant. Myopia-awareness programs also did not reach significance: +0.08 D/year, with a 95% CI from −0.06 to +0.22.

The numerical gap between LLRL and outdoor activity is large: the point estimates differ by roughly 4.4-fold. That ratio should not be treated as a precise comparison, because both estimates have uncertainty and the analysis combines indirect as well as direct comparisons. Still, this is the strongest prevention-specific ranking currently available.

It does not settle the question of which intervention should lead globally. The trials were conducted in China, India, and Taiwan. A result in predominantly East Asian pediatric populations cannot automatically travel to North American, European, Middle Eastern, or older child populations.

Why outdoor time still belongs at the center

Outdoor activity had the smaller measured effect in the network analysis, but it has advantages that no prescription drop or device can match: it is accessible, inexpensive, and does not require a clinic visit. An umbrella review of systematic reviews found consistent evidence that time outdoors is associated with lower myopia incidence and slower progression in children.

Researchers propose that brighter outdoor environments affect retinal signaling, possibly including dopamine-related pathways, and may reduce axial elongation. That remains a proposed mechanism, not proof that a particular light level prevents myopia. A short-term experiment in young adults found that mild and moderate illumination altered choroidal thickness and axial length, but young-adult, short-term ocular measurements cannot establish a pediatric prevention dose.

China's prevention framework includes outdoor activity among its recommended approaches. A 2023 systematic review of that framework also places outdoor time within a broader public-health strategy. For parents, the actionable point is less glamorous than a glowing device: regular outdoor exposure is the intervention with meaningful evidence and the fewest barriers. Existing guidance commonly aims for one to two hours daily.

Red light has a signal, and several unresolved questions

LLRL usually uses roughly 650 nm light in two three-minute sessions per day. Meta-analyses in children who already have myopia report slower axial elongation and refractive progression with repeated low-level red light. For example, a 2024 meta-analysis of randomized trials found efficacy in myopic children and reported no major adverse events across pooled trials.

That evidence supports LLRL as a plausible myopia-control treatment in already-myopic children. It cannot answer every prevention question in children whose eyes are still emmetropizing. The prevention meta-analysis reported photophobia and allergic conjunctivitis as the main adverse events, but longer-term retinal safety in young, non-myopic eyes has not been systematically established.

A longitudinal study of children receiving repeated red-light therapy found that choroidal thickening predicted later myopia-control outcomes. This makes choroidal change a potential response biomarker; it does not prove that choroidal thickening causes the benefit. A 2026 multicenter cohort of 538 pediatric patients likewise identified early axial and choroidal changes as key predictors of treatment response, suggesting that children may not respond uniformly.

Availability matters as much as the ranking. Cleared devices and standardized protocols are concentrated in China, with limited regulatory availability in many Western countries. Where LLRL is authorized, families should discuss it with a pediatric ophthalmologist rather than treating it as a general wellness gadget. Eyes are not houseplants; more light is not automatically better.

Atropine is established, but prevention dosing is unsettled

Low-dose atropine ranked second in the prevention network meta-analysis, with a statistically significant +0.33 D/year refractive benefit. It also has a more established pharmacological profile than the other non-optical options and appears in China's policy recommendations.

Yet the prevention evidence does not separate atropine concentrations. It therefore cannot tell families whether 0.01%, 0.025%, or 0.05% is the best preventive dose in a child who is not yet myopic. It also does not establish whether stopping treatment produces rebound in that population. Those are clinical decisions, particularly relevant for children with a strong family history of early myopia.

HAL spectacles need a confirmatory trial

Highly aspherical lenslet (HAL) spectacles have a compliance story, not a clean prevention win. In a 2024 randomized trial of 108 pre-myopic, low-hyperopic Chinese children followed for one year, the full-sample primary outcomes were not statistically significant. Axial elongation was 0.19 mm with HAL lenses versus 0.24 mm in controls (p=0.057), and refractive change was −0.23 D versus −0.19 D (p=0.883).

Among children who wore HAL lenses more than 30 hours per week, axial elongation was lower: 0.11 mm (95% CI, 0.05 to 0.17) versus 0.27 mm (95% CI, 0.21 to 0.33), p<0.001. The result may indicate a dose-response relationship, but it comes from a compliance-defined subgroup and requires roughly 4.3 hours of daily wear. As the trial report makes clear, the primary full-sample analysis did not confirm the effect.

Sleep is good for children, but it is not proven myopia prevention

Sleep deserves attention for health, mood, learning, and family peace. It does not currently deserve priority as a myopia-specific intervention. A 2023 systematic review of 17 studies found conflicting results for sleep duration, timing, quality, and latency.

Some analyses linked an additional hour of sleep with a 10% lower myopia risk. Another associated more than eight hours with higher myopia prevalence. A propensity-score-matched analysis removed a previously significant association, which points toward confounding by correlated behaviors. The single study using wrist-worn actigraphy found no correlation between sleep measures and either refractive change or axial elongation.

Late bedtimes may track screen exposure and near work rather than a direct effect of sleep biology on eye growth. Reducing screens and near work before bedtime can be sensible, but current evidence does not show that extending sleep duration prevents myopia.

What parents can reasonably do now

• Prioritize daily outdoor time. It has consistent support, no treatment-specific safety concern, and broad public-health relevance.
• Get risk assessed early. Children with myopic parents, siblings with early-onset myopia, or signs of declining distance vision warrant an eye-care discussion.
• Discuss atropine or authorized LLRL with a pediatric ophthalmologist when risk is high. LLRL leads one prevention ranking, but its geographic generalizability and long-term prevention safety remain uncertain.
• Do not buy HAL lenses or optimize bedtime solely for a myopia-prevention claim. HAL's primary trial result was null, and sleep evidence remains inconsistent.

Prevention trials have followed children for no more than about 36 months. They show that some approaches can slow short-term refractive change; they do not yet show that any intervention permanently prevents myopia.

The current evidence supports a calm hierarchy: outdoor time first, clinician-guided treatment for children at higher risk, and skepticism toward sleep-based claims. Red light may become a larger part of prevention care, but it needs replication beyond the populations in which it has been studied and longer safety follow-up in pre-myopic children.